Aura Biosciences, Inc. (AURA) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-11

Key Insights

Matrix Capital Management Company, LP (a 10% owner and director) sold 6,922,870 shares of AURA on 05/07/2026 at $5.64 per share, representing a significant equity reduction by a major insider stakeholder.
The sale resulted in zero shares beneficially owned following the transaction, indicating a complete exit of the position by Matrix Capital Management and its Managing General Partner David E. Goel.
The filing includes a disclaimer that the reporting persons do not admit beneficial ownership except to the extent of pecuniary interest, suggesting potential complexity around the fund structure and voting rights.
The transaction value exceeds $39 million (6.9M shares × $5.64), representing a material liquidation of insider holdings that may signal loss of confidence or rebalancing of the fund's portfolio.

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-16

The reporting person, Conor Kilroy, sold 11,738 shares of Aura Biosciences, Inc. (AURA) common stock at a weighted average price of $7.02 per share. This appears to be an automatic sale to cover tax withholding obligations related to the vesting of restricted stock units.
The sale represents a small portion (5.4%) of Kilroy's total beneficial ownership of 217,835 shares, suggesting this was a routine transaction and not a significant change in his position.
Insider selling can sometimes signal lack of confidence in the company's future prospects, but the context and size of the transaction suggest this was likely a standard practice rather than a concerning signal.

Filed: 2026-01-20

The reporting person, Elisabet de los Pinos, is the President and Chief Executive Officer of Aura Biosciences, Inc. and has significant beneficial ownership in the company.
The reporting person sold 16,928 shares of common stock at a weighted average price of $4.86 to cover tax withholding obligations related to the vesting of restricted stock units.
The reporting person also holds an indirect beneficial ownership of 127,763 shares of common stock through the Elisabet de los Pinos Revocable Trust.

Filed: 2026-01-20

The reporting person, Amy Elazzouzi, who is the Senior Vice President of Finance at Aura Biosciences, Inc., sold 1,581 shares of the company's common stock at $4.86 per share.
The sale was to cover tax withholding obligations in connection with the vesting of restricted stock units, and was not at the discretion of the reporting person.
The reporting person still holds 84,081 shares of the company's common stock, indicating they maintain a significant ownership stake.

Other reports for Aura Biosciences, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.